GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Net Change in Cash

Mayne Pharma Group (ASX:MYX) Net Change in Cash : A$-55.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Mayne Pharma Group's Net Change in Cash for the six months ended in Dec. 2024 was A$-56.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was A$-55.5 Mil.

Mayne Pharma Group Net Change in Cash Historical Data

The historical data trend for Mayne Pharma Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Net Change in Cash Chart

Mayne Pharma Group Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.78 -39.81 -1.31 -4.06 17.45

Mayne Pharma Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.87 -82.93 16.61 0.84 -56.36

Mayne Pharma Group Net Change in Cash Calculation

Mayne Pharma Group's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-15.3+53.449+-19.85+-0.847
=17.5

Mayne Pharma Group's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-13.03+-44.994+-0.26+1.926
=-56.4

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-55.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Net Change in Cash
Comparable Companies
ASX:FRE LLY JNJ ABBV OCSE:NOVO B XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 XTER:BAYN
Traded in Other Exchanges
MAYNF:USA HG6:Germany
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Website
http://www.maynepharma.com
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.